Markus Hoffmann

35.9k total citations · 6 hit papers
116 papers, 18.9k citations indexed

About

Markus Hoffmann is a scholar working on Infectious Diseases, Epidemiology and Molecular Biology. According to data from OpenAlex, Markus Hoffmann has authored 116 papers receiving a total of 18.9k indexed citations (citations by other indexed papers that have themselves been cited), including 89 papers in Infectious Diseases, 31 papers in Epidemiology and 18 papers in Molecular Biology. Recurrent topics in Markus Hoffmann's work include SARS-CoV-2 and COVID-19 Research (71 papers), COVID-19 Clinical Research Studies (36 papers) and Animal Virus Infections Studies (17 papers). Markus Hoffmann is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (71 papers), COVID-19 Clinical Research Studies (36 papers) and Animal Virus Infections Studies (17 papers). Markus Hoffmann collaborates with scholars based in Germany, United States and Sweden. Markus Hoffmann's co-authors include Stefan Pöhlmann, Hannah Kleine‐Weber, Nadine Krüger, Christian Drosten, Marcel A. Müller, Georg Herrler, Simon Schroeder, Andreas Nitsche, Tobias S. Schiergens and Tanja Herrler and has published in prestigious journals such as Nature, Cell and Nucleic Acids Research.

In The Last Decade

Markus Hoffmann

112 papers receiving 18.5k citations

Hit Papers

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is ... 2020 2026 2022 2024 2020 2020 2021 2021 2020 4.0k 8.0k 12.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
    2020 13.3k citations Markus Hoffmann, Nadine Krüger et al. Cell profile →
  2. A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells
    2020 1.2k citations Markus Hoffmann, Stefan Pöhlmann et al. profile →
  3. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
    2021 563 citations Markus Hoffmann, Prerna Arora et al. Cell profile →
  4. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic
    2021 557 citations Markus Hoffmann, Nadine Krüger et al. Cell profile →
  5. Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies
    2020 387 citations Daniel Wrapp, Dorien De Vlieger et al. Cell profile →
  6. SARS-CoV-2 BA.2.86 enters lung cells and evades neutralizing antibodies with high efficiency
    2024 49 citations Lu Zhang, Amy Kempf et al. Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Markus Hoffmann Germany 32 14.2k 3.7k 3.7k 2.0k 1.7k 116 18.9k
Nadine Krüger Germany 16 11.7k 0.8× 2.8k 0.8× 3.4k 0.9× 1.5k 0.8× 1.3k 0.7× 40 15.5k
Hannah Kleine‐Weber Germany 9 11.5k 0.8× 2.7k 0.7× 3.4k 0.9× 1.5k 0.8× 1.2k 0.7× 12 15.3k
Tobias S. Schiergens Germany 22 9.9k 0.7× 2.5k 0.7× 3.2k 0.9× 1.4k 0.7× 1.2k 0.7× 79 14.6k
Simon Schroeder Germany 8 10.0k 0.7× 2.4k 0.6× 3.2k 0.9× 1.3k 0.7× 1.1k 0.6× 9 13.6k
Tanja Herrler Germany 15 9.9k 0.7× 3.5k 0.9× 3.3k 0.9× 1.6k 0.8× 1.2k 0.7× 40 16.2k
Fang Li China 48 16.3k 1.1× 4.2k 1.1× 2.3k 0.6× 1.6k 0.8× 1.7k 1.0× 148 21.2k
Georg Herrler Germany 49 13.3k 0.9× 4.0k 1.1× 3.3k 0.9× 2.2k 1.1× 3.5k 2.1× 165 20.2k
Marcel A. Müller Germany 58 23.9k 1.7× 4.8k 1.3× 4.6k 1.3× 2.4k 1.2× 3.2k 1.9× 140 31.4k
Bart L. Haagmans Netherlands 74 17.2k 1.2× 3.5k 1.0× 2.2k 0.6× 2.5k 1.3× 4.1k 2.4× 245 24.6k
Stefan Pöhlmann Germany 64 21.3k 1.5× 5.8k 1.6× 4.5k 1.2× 5.5k 2.8× 3.9k 2.3× 231 30.8k

Countries citing papers authored by Markus Hoffmann

Since Specialization
Citations

This map shows the geographic impact of Markus Hoffmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus Hoffmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus Hoffmann more than expected).

Fields of papers citing papers by Markus Hoffmann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Markus Hoffmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus Hoffmann. The network helps show where Markus Hoffmann may publish in the future.

Co-authorship network of co-authors of Markus Hoffmann

This figure shows the co-authorship network connecting the top 25 collaborators of Markus Hoffmann. A scholar is included among the top collaborators of Markus Hoffmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Markus Hoffmann. Markus Hoffmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hoffmann, Markus, Susanne Hille, Martin Laudien, et al.. (2025). Mechanistic insights into HPV-positivity in non-smokers and HPV-negativity in smokers with head and neck cancer. Frontiers in Oncology. 14. 1484319–1484319. 1 indexed citations
2.
Hempel, Tim, Jonathan H. Shrimp, Nina Moor, et al.. (2025). Simulations and active learning enable efficient identification of an experimentally-validated broad coronavirus inhibitor. Nature Communications. 16(1). 6949–6949.
3.
Zhang, Lu, Amy Kempf, Inga Nehlmeier, et al.. (2025). Neutralizing activity against bovine H5N1 HPAIV (clade 2.3.4.4b) in human plasma after seasonal influenza vaccination. Emerging Microbes & Infections. 14(1). 2528539–2528539. 2 indexed citations
4.
Happle, Christine, Markus Hoffmann, Metodi V. Stankov, et al.. (2025). Effects of LP.8.1-adapted mRNA vaccination on SARS-CoV-2 variant neutralisation. The Lancet Infectious Diseases. 26(1). e3–e5.
5.
Nowak, Rafał, et al.. (2024). TMPRSS2-specific antisense oligonucleotides inhibit host cell entry of emerging viruses. Virology. 600. 110218–110218. 2 indexed citations
6.
7.
Schulz, Sebastian, Amy Kempf, Inga Nehlmeier, et al.. (2024). Comparative Analysis of Host Cell Entry Efficiency and Neutralization Sensitivity of Emerging SARS-CoV-2 Lineages KP.2, KP.2.3, KP.3, and LB.1. Vaccines. 12(11). 1236–1236. 2 indexed citations
8.
Zhang, Lu, Alexandra Dopfer‐Jablonka, Inga Nehlmeier, et al.. (2024). Virological Traits of the SARS-CoV-2 BA.2.87.1 Lineage. Vaccines. 12(5). 487–487. 2 indexed citations
9.
Wressnigg, Nina, Susanne Eder-Lingelbach, Anders Lilja, et al.. (2023). EFFECTS OF HOMOLOGOUS AND HETEROLOGOUS BOOSTER VACCINATIONS OF THE INACTIVATED DUAL-ADJUVANTED VACCINE VLA2001 AGAINST COVID-19 INCLUDING VARIANTS OF CONCERN: A PHASE 3 RANDOMIZED CLINICAL TRIAL. International Journal of Infectious Diseases. 130. S25–S25. 1 indexed citations
10.
Jacobsen, Henning, Markus Hoffmann, Amy Kempf, et al.. (2023). TMPRSS2 Is Essential for SARS-CoV-2 Beta and Omicron Infection. Viruses. 15(2). 271–271. 38 indexed citations
11.
Chaudhry, M. Zeeshan, Kathrin Eschke, Markus Hoffmann, et al.. (2022). Rapid SARS-CoV-2 Adaptation to Available Cellular Proteases. Journal of Virology. 96(5). e0218621–e0218621. 24 indexed citations
12.
Wagoner, Jessica, Tien-Ying Hsiang, Aleksandr Ianevski, et al.. (2022). Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2. Microbiology Spectrum. 10(5). e0333122–e0333122. 34 indexed citations
13.
Sidarovich, Anzhalika, Nadine Krüger, Cheila Rocha, et al.. (2022). Host Cell Entry and Neutralization Sensitivity of SARS-CoV-2 Lineages B.1.620 and R.1. Viruses. 14(11). 2475–2475. 1 indexed citations
14.
Arora, Prerna, Lu Zhang, Cheila Rocha, et al.. (2022). The SARS-CoV-2 Delta-Omicron Recombinant Lineage (XD) Exhibits Immune-Escape Properties Similar to the Omicron (BA.1) Variant. International Journal of Molecular Sciences. 23(22). 14057–14057. 4 indexed citations
15.
Wettstein, Lukas, Christian Kersten, Tatjana Weil, et al.. (2022). Peptidomimetic inhibitors of TMPRSS2 block SARS-CoV-2 infection in cell culture. Communications Biology. 5(1). 681–681. 17 indexed citations
16.
Hammerschmidt, Swantje I., Berislav Bošnjak, Günter Bernhardt, et al.. (2021). Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination. Cellular and Molecular Immunology. 18(10). 2455–2456. 29 indexed citations
17.
Hoffmann, Markus, Heike Hofmann-Winkler, Nadine Krüger, et al.. (2021). SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination. Cell Reports. 36(3). 109415–109415. 162 indexed citations
18.
Arora, Prerna, Cheila Rocha, Amy Kempf, et al.. (2021). The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency. Cellular and Molecular Immunology. 18(12). 2673–2675. 29 indexed citations
19.
Arora, Prerna, Anzhalika Sidarovich, Nadine Krüger, et al.. (2021). B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination. Cell Reports. 37(2). 109825–109825. 56 indexed citations
20.
Wrapp, Daniel, Dorien De Vlieger, Kizzmekia S. Corbett, et al.. (2020). Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies. Cell. 181(5). 1004–1015.e15. 387 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nadine Krüger Breakdown of academic impact, for papers by Hannah Kleine‐Weber Breakdown of academic impact, for papers by Tobias S. Schiergens Breakdown of academic impact, for papers by Simon Schroeder Breakdown of academic impact, for papers by Tanja Herrler Breakdown of academic impact, for papers by Fang Li Breakdown of academic impact, for papers by Georg Herrler Breakdown of academic impact, for papers by Marcel A. Müller Breakdown of academic impact, for papers by Bart L. Haagmans Breakdown of academic impact, for papers by Stefan Pöhlmann
Rankless by CCL
2026